BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Euronext Paris 07:19:35 2024-05-02 am EDT | ||
| 9.06 EUR | +2.52% |
|
| 1 month | +20.54% | ||
| 3 months | +23.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 9.06 | +2.52% | 53 |
| 24-04-30 | 8.837 | -0.29% | 70 |
| 24-04-29 | 8.863 | -0.24% | 108 |
| 24-04-26 | 8.884 | +0.82% | 108 |
| 24-04-25 | 8.812 | +9.60% | 103 |
Real-time Euronext Paris
Last update May 02, 2024 at 07:19 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| C4J6Z | |
| ISIN | DE000CU1CD84 |
| Date issued | 2019-04-01 |
| Strike | 4,491 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.42 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.184 € |
|---|---|
| Lowest since issue | 1.9 € |
| Spread | 0.006 € |
| Spread % | 0.07% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
- Stock Market
- Certificates
- C4J6Z Certificat
